You are here: Industry Insights > Akcea

News List

Eyeing Novartis deal, Akcea trumpets lipoprotein drug data pharmaphorum
December 11, 2018
Ionis affiliate Akcea Pharma has new data for its antisense drug for elevated lipoprotein levels in patients with cardiovascular disease that it hopes will entice Novartis into a licensing deal......
US nod for Akcea/Ionis’ Tegsedi pharmatimes
October 11, 2018
Akcea and Ionis’ Tegsedi has won US approval for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid...
PTC Therapeutics to commercialise Akcea’s two rare disease drugs pharmaceutical-technology
August 06, 2018
Ionis Pharmaceuticals affiliate Akcea Therapeutics has signed an agreement with biopharmaceutical company PTC Therapeutics for the commercialisation of its rare disease drugs Tegsedi (inotersen) and Waylivra (volanesorsen) in Latin America.
Ionis Pharmaceuticals Partners With Akcea Therapeutics in a Potential $1.7 Billion Deal biospace
March 16, 2018
In 2017, GlaxoSmithKline ended its partnership with Ionis Pharmaceuticals, Inc. to develop and market inotersen and a follow-up drug for rare diseases
Akcea’s rare lipid disorder drug wins PIM status pharmatimes
October 11, 2017
Akcea Therapeutics’s volanesorsen has been granted a Promising Innovative Medicine designation by the Medicines and Healthcare products Regulatory Agency for the treatment of familial chylomicronaemia syndrome , a rare genetic lipid disorder.

Previous page 1 2 Next page